Antithrombotic medications, particularly antiplatelet agents, are crucial in the management of patients with acute coronary syndromes. Their potential to increase the risk of bleeding, however, represents the downside of their remarkable efficacy in terms of prevention of ischaemic events. Careful assessment of the benefit/risk ratio of the medications that are currently available is therefore essential.
Les anti-agrégants plaquettaires dans les syndromes coronaires aigus : rapport bénéfice/risque
DONATACCIO, Maria Pia;
2012-01-01
Abstract
Antithrombotic medications, particularly antiplatelet agents, are crucial in the management of patients with acute coronary syndromes. Their potential to increase the risk of bleeding, however, represents the downside of their remarkable efficacy in terms of prevention of ischaemic events. Careful assessment of the benefit/risk ratio of the medications that are currently available is therefore essential.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
